Usefulness of Olfactory Bulb Measurement in 3D-FIESTA in Differentiating Parkinson Disease from Atypical Parkinsonism

References

1. 1.↵
   1. Gibb W,
   2. Lees A

   . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson disease. J Neurol Neurosurg Psychiatry 1988;51:745–52.doi:10.1136/jnnp.51.6.745 pmid:2841426

   Abstract/FREE Full Text
2. 2.↵
   1. Hummel T,
   2. Witt M,
   3. Reichmann H, et al

   . Immunohistochemical, volumetric, and functional neuroimaging studies in patients with idiopathic Parkinson disease. J Neurol Sci 2010;289:119–22 doi:10.1016/j.jns.2009.08.026 pmid:19775703

   CrossRefPubMed
3. 3.↵
   1. Huisman E,
   2. Uylings HB,
   3. Hoogland PV

   . A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson disease. Mov Disord 2004;19:687–92 doi:10.1002/mds.10713 pmid:15197709

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Herting B,
   2. Schulze S,
   3. Reichmann H, et al

   . A longitudinal study of olfactory function in patients with idiopathic Parkinson disease. J Neurol 2008;255:367–70 doi:10.1007/s00415-008-0665-5 pmid:18343969

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Savoiardo M

   . Differential diagnosis of Parkinson disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 2003;24 Suppl 1:s35–37 doi:10.1007/s100720300036 pmid:12774211

   CrossRefPubMed
6. 6.↵
   1. Doty RL

   . Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 2012;8:329–39 doi:10.1038/nrneurol.2012.80 pmid:22584158

   CrossRefPubMed
7. 7.↵
   1. Goldstein DS,
   2. Holmes C,
   3. Bentho O, et al

   . Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14:600–07 doi:10.1016/j.parkreldis.2008.01.010 pmid:18325818

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Suchowersky O,
   2. Reich S,
   3. Perlmutter J, et al

   ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2006;66:968–75 doi:10.1212/01.wnl.0000215437.80053.d0 pmid:16606907

   Abstract/FREE Full Text
9. 9.↵
   1. Altınayar S,
   2. Oner S,
   3. Can S, et al

   . Olfactory disfunction and its relation olfactory bulb volume in Parkinsons disease. Eur Rev Med Pharmacol Sci 2014;18:3659–64 pmid:25535137

   PubMed
10. 10.↵
    1. Brodoehl S,
    2. Klingner C,
    3. Volk GF, et al

    . Decreased olfactory bulb volume in idiopathic Parkinson disease detected by 3.0‐Tesla magnetic resonance imaging. Mov Disord 2012;27:1019–25 doi:10.1002/mds.25087 pmid:22730050

    CrossRefPubMed
11. 11.↵
    1. Wang J,
    2. You H,
    3. Liu J-F, et al

    . Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. AJNR Am J Neuroradiol 2011;32:677–81 doi:10.3174/ajnr.A2350 pmid:21330398

    Abstract/FREE Full Text
12. 12.↵
    1. Sengoku R,
    2. Matsushima S,
    3. Bono K, et al

    . Olfactory function combined with morphology distinguishes Parkinson disease. Parkinsonism Relat Disord 2015;21:771–77.doi:10.1016/j.parkreldis.2015.05.001 pmid:25986741

    CrossRefPubMed
13. 13.↵
    1. Dutta D,
    2. Karthik K,
    3. Holla VV, et al

    . Olfactory bulb volume, olfactory sulcus depth in Parkinson disease, atypical parkinsonism. Mov Disord Clin Pract 2023;10:794–801 doi:10.1002/mdc3.13733 pmid:37205255

    CrossRefPubMed
14. 14.↵
    1. Miyata M,
    2. Kakeda S,
    3. Hashimoto T, et al

    . Facial nerve atrophy in patients with amyotrophic lateral sclerosis: evaluation with fast imaging employing steady‐state acquisition (FIESTA). J Magn Reson Imaging 2020;51:757–66 doi:10.1002/jmri.26890 pmid:31400058

    CrossRefPubMed
15. 15.↵
    1. Postuma RB,
    2. Berg D,
    3. Stern M, et al

    . MDS clinical diagnostic criteria for Parkinson disease. Mov Disord 2015;30:1591–601 doi:10.1002/mds.26424 pmid:26474316

    CrossRefPubMed
16. 16.↵
    1. Armstrong MJ,
    2. Litvan I,
    3. Lang AE, et al

    . Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503 doi:10.1212/WNL.0b013e31827f0fd1 pmid:23359374

    Abstract/FREE Full Text
17. 17.↵
    1. Wenning GK,
    2. Stankovic I,
    3. Vignatelli L, et al

    . The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 2022;37:1131–48 doi:10.1002/mds.29005 pmid:35445419

    CrossRefPubMed
18. 18.↵
    1. Litvan I,
    2. Agid Y,
    3. Calne D, et al

    . Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9 doi:10.1212/wnl.47.1.1 pmid:8710059

    Abstract/FREE Full Text
19. 19.↵
    1. Winikates J,
    2. Jankovic J

    . Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98–102 doi:10.1001/archneur.56.1.98 pmid:9923767

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Elble RJ

    . Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000;54:S2–6 pmid:10854344

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Shin HW,
    2. Chung SJ

    . Drug-induced parkinsonism. J Clin Neurol 2012;8:15–21 doi:10.3988/jcn.2012.8.1.15 pmid:22523509

    CrossRefPubMed
22. 22.↵
    1. Soliveri P,
    2. Monza D,
    3. Paridi D, et al

    . Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999;53:502–07 doi:10.1212/wnl.53.3.502 pmid:10449111

    Abstract/FREE Full Text
23. 23.↵
    1. Koyama M,
    2. Yagishita A,
    3. Nakata Y, et al

    . Imaging of corticobasal degeneration syndrome. Neuroradiology 2007;49:905–12 doi:10.1007/s00234-007-0265-6 pmid:17632713

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Landis JR,
    2. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 pmid:843571

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Nielsen T,
    2. Jensen MB,
    3. Stenager E, et al

    . The use of olfactory testing when diagnosing Parkinson disease-a systematic review. Dan Medi J 2018;65:A5481 pmid:29726318

    PubMed
26. 26.↵
    1. Son G,
    2. Jahanshahi A,
    3. Yoo S-J, et al

    . Olfactory neuropathology in Alzheimer’s disease: a sign of ongoing neurodegeneration. BMB Rep 2021;54:295–304 doi:10.5483/BMBRep.2021.54.6.055 pmid:34162463

    CrossRefPubMed
27. 27.↵
    1. Kägi G,
    2. Bhatia KP,
    3. Tolosa E

    . The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5–12 doi:10.1136/jnnp.2008.157370 pmid:20019219

    Abstract/FREE Full Text
28. 28.↵
    1. Miyata M,
    2. Kakeda S,
    3. Toyoshima Y, et al

    . Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson disease. Neuroradiology 2019;61:1251–59 doi:10.1007/s00234-019-02253-6 pmid:31267152

    CrossRefPubMed
29. 29.↵
    1. Goldman JG,
    2. Bledsoe IO,
    3. Merkitch D, et al

    . Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. Neurology 2017;88:1265–72 doi:10.1212/WNL.0000000000003764 pmid:28235816

    Abstract/FREE Full Text
30. 30.↵
    1. Low A,
    2. Foo H,
    3. Yong TT, et al

    . Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson disease. J Neurol Neurosurg Psychiatry 2019;90:681–87 doi:10.1136/jnnp-2018-319592

    Abstract/FREE Full Text
31. 31.↵
    1. Jin C,
    2. Qi S,
    3. Teng Y, et al

    . Integrating structural and functional interhemispheric brain connectivity of gait freezing in Parkinson disease. Front Neurol 2021;12:60986 doi:10.3389/fneur.2021.609866 pmid:33935931

    CrossRefPubMed